Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that ~20% of all chronic low back pain derives from the sacroiliac joint.
Initial enrollment of an earlier U.S. 10-site EVoluSIon Study commenced in 1Q15. Zyga was among companies helping to fuel the lively discussion of SI joint treatment at the NASS meeting in 2015, as well.
Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that 0% of all chronic...
Zyga Technology enrolled the first four patients in an expanded EVoluSIon Clinical Study. The prospective 40-site, 250-patient trial will evaluate long-term fusion and pain reduction in patients receiving SImmetry® Sacroiliac Joint Fusion.
The company cited figures from Expert Review of Neurotherapeutics, reporting that ~20% of all chronic low back pain derives from the sacroiliac joint.
Initial enrollment of an earlier U.S. 10-site EVoluSIon Study commenced in 1Q15. Zyga was among companies helping to fuel the lively discussion of SI joint treatment at the NASS meeting in 2015, as well.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
